Announcements
OICR's Board of Directors has approved funding of the Personalized Medicine Research Fund competition held in November 2010. The following table provides listings of grants with funding amounts. The funding amount includes eligible institutional overhead costs.
Thank you to all the applicants who submitted an application to the Personalized Medicine Research Fund competition. The panel feedback and critique will be mailed out to all successful and unsuccessful applicants in the next two weeks.
OICR congratulates the successful applicants and wishes all applicants success in their research endeavours.
PERSONALIZED MEDICINE RESEARCH FUND – ROUND I COMPETITION 2011-12
Investigator |
Institution |
Project title |
Budget |
Period (years) |
Rob Bristow |
UHN |
Augmin-Centrosome Complexes: A Novel Marker for Prostate Cancer Aggression/Progression |
$651,685 |
3 |
Bharati Bapat |
Samuel Lunenfeld Research Institute |
Analysis of novel methylation biomarkers distinguishing aggressive from indolent prostate cancer |
$619,440 |
3 |
Aaron Schimmer |
Ontario Cancer Institute |
Toll-like receptor activation as a therapeutic strategy for the treatment of leukemia |
$458,280 |
2 |
Fei-Fei Liu |
UHN |
Micro-RNA and mRNA Expression Profiling to Predict Outcome and Characterize the Cervix Cancer Microenvironment |
$634,407 |
3 |
Eleftherios Diamandis |
Mount Sinai Hospital |
An Integrated Proteomic Approach to Novel Pancreatic Cancer Biomarker Discovery |
$476,184 |
3 |
Peeyush Lala |
UWO |
COX-2 mediated induction of stem cell phenotype in human breast cancer and identification of therapeutic targets |
$602,787 |
3 |
Laura Curiel |
Thunder Bay Regional Research Institute |
Antibody-labeled Magnetic Resonance Guidance for Non Invasive Localized Prostate Cancer Treatment |
$282,151 |
3 |
Geoffrey Liu |
UHN |
Pharmacogenetic Study of Gemcitabine in Pancreatic Cancer: Analysis of Clinical and Observational Trials |
$303,812 |
2 |
Aaron Schimmer |
OCI |
A phase I clinical trial of a mitochondrial protein synthesis inhibitor in patients with relapsed or refractory AML |
$638,820 |
3 |
Vuk Stambolic |
UHN |
Identification of predictive biomarkers of metformin benefit in women with early stage breast cancer enrolled in MA.32, a phase III trial of the effect of metformin on recurrence and survival in early stage of breast cancer |
$694,440 |
3 |
Grand Total |
$5,362,006 |
